BridgeMD
New treatment option for Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Official title Linezolid Plus Standard of Care
ClinicalTrials.gov ID: NCT06958835
What this study is testing
What is Linezolid 600 mg?
Linezolid 600 mg is an investigational medicine, given as a twice-daily pill taken by mouth, being studied as a potential treatment for staphylococcus aureus bloodstream infections (bsi; bacteremia).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Staphylococcus aureus (S. aureus) grown from at least one blood culture
- Hospitalised at a participating centre
- ≥18 years old
- Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements
You likely can't join if
- Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus
- Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment
- Necrotising fasciitis
- Currently receiving linezolid or clindamycin
- Use of any monoamine oxidase A or B inhibitor within the last two weeks
- Known hypersensitivity to linezolid or any other ingredients of the study drugs
See the full eligibility criteria
- Staphylococcus aureus (S. aureus) grown from at least one blood culture
- Hospitalised at a participating centre
- ≥18 years old
- Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements
- Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus
- Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment
- Necrotising fasciitis
- Currently receiving linezolid or clindamycin
- Use of any monoamine oxidase A or B inhibitor within the last two weeks
- Known hypersensitivity to linezolid or any other ingredients of the study drugs
- Current severe thrombocytopenia (i.e. \<30 x 10\^9/L)
- Application of study drug not possible (per mouth or per gastric tube)
- Currently breastfeeding
- Local treating team believes that death is imminent and inevitable
- Patient is receiving end of life care and antibiotic treatment is not considered appropriate
- Local treating team believes that participation in the study is not in the best interest of the patient
- Any indication that the patient is unwilling to participate in the study including an advance directive stating such unwillingness
The study team makes the final eligibility decision.
Where it's taking place
- Aarau, Canton of Aargau, Switzerland
- Basel, Canton of Basel-City, Switzerland
- Bern, Canton of Bern, Switzerland
- Geneva, Canton of Geneva, Switzerland
- Delémont, Canton of Jura, Switzerland
- Sankt Gallen, Canton of St. Gallen, Switzerland
- Lausanne, Canton of Vaud, Switzerland
- Winterthur, Canton of Zurich, Switzerland
- Zurich, Canton of Zurich, Switzerland
- Lugano, Canton Ticino, Switzerland
- Basel, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarau, Canton of Aargau, Switzerland; Basel, Canton of Basel-City, Switzerland; Bern, Canton of Bern, Switzerland; Geneva, Canton of Geneva, Switzerland; Delémont, Canton of Jura, Switzerland; Sankt Gallen, Canton of St. Gallen, Switzerland and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.